PL2376533T3 - Preparat przeciwciała - Google Patents

Preparat przeciwciała

Info

Publication number
PL2376533T3
PL2376533T3 PL09764858.8T PL09764858T PL2376533T3 PL 2376533 T3 PL2376533 T3 PL 2376533T3 PL 09764858 T PL09764858 T PL 09764858T PL 2376533 T3 PL2376533 T3 PL 2376533T3
Authority
PL
Poland
Prior art keywords
antibody preparation
antibody
preparation
Prior art date
Application number
PL09764858.8T
Other languages
English (en)
Inventor
Joachim Momm
Hans-Joachim Wallny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2376533(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of PL2376533T3 publication Critical patent/PL2376533T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL09764858.8T 2008-12-10 2009-12-09 Preparat przeciwciała PL2376533T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation

Publications (1)

Publication Number Publication Date
PL2376533T3 true PL2376533T3 (pl) 2016-09-30

Family

ID=40637230

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16162699T PL3072906T3 (pl) 2008-12-10 2009-12-09 Preparat przeciwciała
PL09764858.8T PL2376533T3 (pl) 2008-12-10 2009-12-09 Preparat przeciwciała

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16162699T PL3072906T3 (pl) 2008-12-10 2009-12-09 Preparat przeciwciała

Country Status (31)

Country Link
US (3) US20110236398A1 (pl)
EP (4) EP2196476A1 (pl)
JP (6) JP6143416B2 (pl)
KR (2) KR20170044211A (pl)
CN (3) CN114225022A (pl)
AU (1) AU2009324371B2 (pl)
BR (1) BRPI0922730A2 (pl)
CA (1) CA2745938C (pl)
CL (1) CL2011001406A1 (pl)
CO (1) CO6361952A2 (pl)
CY (2) CY1117735T1 (pl)
DK (2) DK3072906T3 (pl)
EC (1) ECSP11011192A (pl)
ES (2) ES2579835T3 (pl)
HR (2) HRP20160754T1 (pl)
HU (2) HUE056626T2 (pl)
IL (3) IL264316B2 (pl)
LT (1) LT3072906T (pl)
MA (1) MA33023B1 (pl)
MX (1) MX2011006242A (pl)
MY (2) MY157772A (pl)
NZ (1) NZ592918A (pl)
PE (1) PE20120342A1 (pl)
PL (2) PL3072906T3 (pl)
PT (2) PT3072906T (pl)
RU (2) RU2745601C2 (pl)
SI (2) SI3072906T1 (pl)
SM (1) SMT201600222B (pl)
TN (1) TN2011000229A1 (pl)
WO (1) WO2010066762A1 (pl)
ZA (1) ZA201103362B (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2810731A1 (en) 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
CA2864539C (en) * 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
SG10201700360VA (en) * 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP3345923A1 (en) * 2012-09-20 2018-07-11 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
AU2013344796B2 (en) * 2012-11-16 2016-11-10 Novartis Ag Use of IL-1 beta binding antibodies for treating peripheral arterial disease
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
EP2968538A1 (en) * 2013-03-15 2016-01-20 Bayer HealthCare LLC Anti-prolactin receptor antibody formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
CA2950392A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
RU2017107847A (ru) * 2014-09-03 2018-10-03 Медиммун Лимитед Стабильный состав на основе антитела к il-4r-альфа
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
SI3386541T1 (sl) 2015-12-07 2020-11-30 Merck Patent Gbmh Vodna farmacevtska formulacija, ki vsebuje protitelo proti PD-1 avelumab
SI3475303T1 (sl) * 2016-06-27 2021-12-31 Morphosys Ag Formulacija protitelesa proti CD19
EP3487584A1 (en) * 2016-07-21 2019-05-29 Novartis AG Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
US10961314B2 (en) * 2016-09-27 2021-03-30 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition comprising an anti-IL-6 receptor antibody
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
JP2020524694A (ja) * 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
RU2020113234A (ru) * 2017-09-13 2021-10-13 Новартис Аг ПРИМЕНЕНИЕ АНТИТЕЛ, СВЯЗЫВАЮЩИХ IL-1β, ДЛЯ ЛЕЧЕНИЯ АЛКОГОЛЬНОГО ГЕПАТИТА
CN112004827A (zh) * 2018-03-23 2020-11-27 艾伯维德国有限责任两合公司 稳定的水性抗tau抗体调配物
MX2020012351A (es) 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
CA3115747A1 (en) 2018-10-10 2020-04-16 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
WO2022135395A1 (zh) * 2020-12-22 2022-06-30 百奥泰生物制药股份有限公司 稳定的抗体制剂及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
WO2002011753A1 (en) * 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CN1798575A (zh) * 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
BRPI0606867A2 (pt) * 2005-01-28 2009-07-21 Wyeth Corp formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
EP1871806A2 (en) * 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
TR201802449T4 (tr) 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
AU2008228823A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
CN104399076B (zh) 2021-09-14
JP2026021446A (ja) 2026-02-10
HUE056626T2 (hu) 2022-02-28
CY1117735T1 (el) 2017-05-17
TN2011000229A1 (en) 2012-12-17
CA2745938C (en) 2018-04-24
IL212922A0 (en) 2011-07-31
EP2376533B1 (en) 2016-03-30
RU2011127913A (ru) 2013-01-20
EP3072906B1 (en) 2021-09-08
RU2563179C2 (ru) 2015-09-20
RU2015132431A (ru) 2018-12-24
HRP20160754T1 (hr) 2016-08-12
US8623367B2 (en) 2014-01-07
DK2376533T3 (en) 2016-06-27
EP3072906A1 (en) 2016-09-28
US20200384108A1 (en) 2020-12-10
JP6143416B2 (ja) 2017-06-07
PT3072906T (pt) 2021-12-14
EP2376533A1 (en) 2011-10-19
AU2009324371A1 (en) 2011-06-23
SI3072906T1 (sl) 2022-01-31
JP2023109938A (ja) 2023-08-08
EP2196476A1 (en) 2010-06-16
CY1124844T1 (el) 2022-11-25
WO2010066762A1 (en) 2010-06-17
ES2900624T3 (es) 2022-03-17
IL212922B (en) 2019-02-28
DK3072906T3 (da) 2021-12-13
IL264316B1 (en) 2023-09-01
IL276622A (en) 2020-09-30
HRP20211899T1 (hr) 2022-03-04
CO6361952A2 (es) 2012-01-20
JP2015231997A (ja) 2015-12-24
CN114225022A (zh) 2022-03-25
CN102245639A (zh) 2011-11-16
KR20120009421A (ko) 2012-01-31
RU2745601C2 (ru) 2021-03-29
US20120315285A1 (en) 2012-12-13
AU2009324371B2 (en) 2013-10-10
IL264316A (en) 2019-02-28
CN104399076A (zh) 2015-03-11
MY166050A (en) 2018-05-22
KR101762966B1 (ko) 2017-07-31
US20110236398A1 (en) 2011-09-29
JP2012511540A (ja) 2012-05-24
CA2745938A1 (en) 2010-06-17
LT3072906T (lt) 2021-12-27
BRPI0922730A2 (en) 2018-11-06
CL2011001406A1 (es) 2012-03-30
SI2376533T1 (sl) 2016-07-29
ECSP11011192A (es) 2011-08-31
ES2579835T3 (es) 2016-08-17
RU2015132431A3 (pl) 2018-12-24
EP3792282A1 (en) 2021-03-17
PL3072906T3 (pl) 2022-01-24
MX2011006242A (es) 2011-06-24
KR20170044211A (ko) 2017-04-24
JP7286595B2 (ja) 2023-06-05
PE20120342A1 (es) 2012-04-24
HK1159130A1 (zh) 2012-07-27
JP2018168158A (ja) 2018-11-01
ZA201103362B (en) 2012-01-25
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
JP2020203889A (ja) 2020-12-24
CN102245639B (zh) 2014-12-24
PT2376533T (pt) 2016-07-13
MA33023B1 (fr) 2012-02-01
SMT201600222B (it) 2016-08-31
HUE028408T2 (en) 2016-12-28
IL264316B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
PL3072906T3 (pl) Preparat przeciwciała
CY2021027I1 (el) Σκευασματα αντισωματων anti-cd20
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
IL212175B (en) Muc1* antibodies
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
EP2358392A4 (en) ANTIBODY FORMULATION
IL287311A (en) Antibodies and processes for preparing the same
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
EP2254911A4 (en) HUMANIZED ANTI-C5aR ANTIBODIES
PL2459167T3 (pl) Preparat podskórny przeciwciała anty-her2
DK2234600T3 (da) Antistofformulering
PT2813570T (pt) Resumo
PT2376116E (pt) Anticorpos anti-igf
PT2406284T (pt) Anticorpos anti-bcma
EP2262831A4 (en) ANTI-properdin antibody
BRPI0912173A2 (pt) anticorpos anti-flt3
BRPI0922800A2 (pt) anticorpos c-met
PT3045471T (pt) Resumo
EP2377932A4 (en) ANTI-Siglec-15 ANTIBODY
DK2252395T3 (da) Afsvovlingsmaterialer
BRPI0918419A2 (pt) nova formulação anticorpo
BRPI0909633A2 (pt) anticorpos anti-tyrp1
EP2207803A4 (en) Cd9-specific human antibodies